Site search

Clear filter
2887 results for '' found
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis
/
A prospective, randomized, single-blinded, sham controlled study of Pelvic Vein Embolization (PVE) for treatment of erectile dysfunction (ED) (ACTRN12620001023943)
A prospective, randomized, single-blinded, sham controlled study of Pelvic Vein Embolization (PVE) for treatment of erectile dysfunction (ED) (ACTRN12620001023943)
/
A Prospective angiOtensin vs. noRadrenaline Trial for Hypotension management to reduce length Of hospital stay in Cardiac Surgery (the PORTHOS study) (ACTRN12623000848606p)
A Prospective angiOtensin vs. noRadrenaline Trial for Hypotension management to reduce length Of hospital stay in Cardiac Surgery (the PORTHOS study) (ACTRN12623000848606p)
/
A phase 2 randomised, open-label trial of maintenance of weight loss with alternate-weekly incretin medication dosing (ACTRN12625000609459)
A phase 2 randomised, open-label trial of maintenance of weight loss with alternate-weekly incretin medication dosing (ACTRN12625000609459)
/
PFOX:  Pulmonary Fibrosis Ambulatory Oxygen Trial (NCT03737409)
PFOX: Pulmonary Fibrosis Ambulatory Oxygen Trial (NCT03737409)
/
A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination with New Hormonal Agents in Pat
A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination with New Hormonal Agents in Pat
/
A Prospective multicentre, phase 2b randomised controlled double-blind trial, to determine the safety and efficacy of perispinal etanercept on quality of life at 28 days post treatment. (ACTRN126
A Prospective multicentre, phase 2b randomised controlled double-blind trial, to determine the safety and efficacy of perispinal etanercept on quality of life at 28 days post treatment. (ACTRN126
/
PERsonalised Selection Of medication for Newly diagnosed Adult epiLepsy (ACTRN12623000209695)
PERsonalised Selection Of medication for Newly diagnosed Adult epiLepsy (ACTRN12623000209695)
/
Perampanel for the prevention of post-stroke epilepsy: a pilot phase II randomised controlled trial (ACTRN12618001984280)
Perampanel for the prevention of post-stroke epilepsy: a pilot phase II randomised controlled trial (ACTRN12618001984280)
/